跳至主要内容
临床试验/RBR-6qx7m5
RBR-6qx7m5进行中(未招募)未知

The role of technology in self-management and adherence to different treatment regimens for insulin-dependent diabetes mellitus

Faculdade de Ciências Médicas da Santa Casa de São Paulo0 个研究点开始时间: 2019年4月22日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
0Y 至 100Y(—)

入选标准

  • Patients under following at ADO with type 1 DM or LADA. Any age. Any A1C. Use of insulin analogues (ultra-slow - Detemir, Glargina 100, Glargina 300, Degludeca - and ultrafast - Glulisine, Aspart or Lispro). In the subgroup of patients under carbohydrate counts, those who have had this modality of treatment for at least 3 (three) months. In the subgroup of patients undergoing treatment with CSII, those who have had this treatment modality for at least 3 (three) months.

排除标准

  • Patients with other types of DM than those previously mentioned. Patients who use insulin, but not in MDI scheme. Patients treated with conventional insulin (NPH - Neutral Protamine Hagedorn - and regular), although in an MDI scheme.

研究者

发起方
Faculdade de Ciências Médicas da Santa Casa de São Paulo

相似试验